RARE Overview
Upcoming Projects (RARE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RARE)
-
A Second Look at setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 randomized, placebo-controlled readout
Tickers: RARE, MREO
Executed On: Dec 12, 2025 at 10:30 AM EST -
A look at Ultragenyx setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 clinical trial readout
Tickers: RARE, MREO
Executed On: Dec 08, 2025 at 02:00 PM EST -
Discussing the implications of the ORBIT trial evaluating setrusumab in osteogenesis imperfecta (OI) following continuation of the trial after the 2nd interim analysis
Ticker: RARE
Executed On: Jul 23, 2025 at 11:30 AM EDT -
Angelman Syndrome Pipeline: Recent Updates on GTX-102 (Ultragenyx & GeneTx), ION582 (Ionis Pharmaceuticals), and rugonersen.
Tickers: OAK HILL BIO, IONS, RARE
Executed On: May 12, 2025 at 04:00 PM EDT -
Discussing the Phase 2/3 Orbit Study of Ultragenyx Pharma's setrusumab (UX143) for Osteogenesis Imperfecta
Ticker: RARE
Executed On: Aug 27, 2024 at 10:30 AM EDT -
Examining the potential of Ultragenyx's DTX401 Phase 3 Trial Results in treating Glycogen Storage Disease Type Ia (GSDIa)
Ticker: RARE
Executed On: Aug 21, 2024 at 03:00 PM EDT -
Discussing the Phase 2/3 Orbit Study of Ultragenyx' Setrusumab (UX143) in treating Osteogenesis Imperfecta
Tickers: RARE, MREO
Executed On: Jun 30, 2023 at 02:00 PM EDT -
A look UX143 (Setrusumab), an Anti-sclerostin Monoclonal Antibody as a potential therapy for osteogenesis imperfecta
Ticker: RARE
Executed On: Jun 08, 2022 at 05:30 AM EDT
Expired Projects (RARE)
-
Discussing Ultragenyx’s UX143 (setrusumab) in treating Osteogenesis Imperfecta
Ticker: RARE
Execute By: Jul 31, 2023 -
What Can Investors Expect from Ultragenyx's rhGUS Phase 3 Data for Patients with MPS7 Coming Mid 2016?
Ticker: RARE
Execute By: Aug 31, 2016
Upcoming & Overdue Catalysts (RARE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RARE)
-
Phase 3 data of Aceneuramic acid extended release (Ace-ER) for GNE Myopathy due 2H 2017
Ticker: RARE
Occurred on: Aug 22, 2017 -
Data from Phase 3 KRN23 for X-Linked Hypophosphatemia in Adults due 1H 2107
Ticker: RARE
Occurred on: Apr 18, 2017 -
Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia Released
Ticker: RARE
Occurred on: Apr 06, 2017 -
UltraGenyx (RARE) Expects Data from Phase 2 Seizure Study of UX007 in Glut1 Deficiency Syndrome (Glut1 DS) Patients in Q1 2017
Ticker: RARE
Occurred on: Mar 22, 2017 -
Phase 2 data of Triheptanoin (UX007) for Long-Chain Fatty Acid Oxidation Disorders due 2H 2016
Ticker: RARE
Occurred on: Nov 30, 2016 -
Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia
Ticker: RARE
Occurred on: Sep 19, 2016 -
Ultragenyx (RARE) Presents Second Set of Interim Phase II Data Evaluating KRN23 in Treatment of Tumor-Induced Osteomalacia
Ticker: RARE
Occurred on: Sep 18, 2016 -
Ultragenyx's rhGUS Phase 3 Data for Patients with MPS7 Due Mid 2016
Ticker: RARE
Occurred on: Jul 14, 2016 -
Ultragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
Ticker: RARE
Occurred on: Jul 14, 2016 -
Phase 2 interim data of KRN23 for Tumor-induced osteomalacia (TIO) due early 2016
Ticker: RARE
Occurred on: Apr 21, 2016
Strategic Initiatives (RARE)
-
Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
Tickers: RARE, TKD.F
Announcement Date: Jun 07, 2016
